Cancer Cancer Malignant neoplasm
Conditions
Interventions
WP1 does not require patients’ participation as the work undertaken will only relate to data obtained from electronic records. Anonymised medical records will be analysed to look for a link with elect
Sponsors
Royal Surrey County Hospital NHS Foundation Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Stakeholders (n=10) 1.1. 5 Medical and Clinical Oncologists, General Practitioners, Geriatricians 1.2. 5 Chemotherapy and Specialist Nurses 2. Patients (n=10) 2.1. 2 patients aged 60 - 70 with newly diagnosed stage II or III breast cancer and 2 >70 years old 2.2. 3 patients with stage 3 colon cancer (1 60 - 70 years old and 2 >70 years old) 2.3. 3 patients with Stage IIIB-IV non-small cell lung cancer (1 - 60-70 years old and 2 >70 years old) 3. Carers (n=5) Purposely selected for gender (men =3, women =2) and relationship to the patient (partner =3 or child =2)
Exclusion criteria
Exclusion criteria: 1. Stakeholders, patients or carers who do not fulfil the criteria described above 2. Are unable to participate in an interview 3. Do not speak/understand English
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Work-package 1: 30 day chemotherapy mortality and hospital admissions during chemotherapy. Information will be taken from historical systemic chemotherapy dataset (SACT) records 2013 - 2016 of patients with breast, lung and colorectal cancer. The data will be obtained from the following databases: The Clinical Practice Research Datalink (CPRD), ResearchOne database and Royal College of GPs (RCGP) Research and Surveillance Centre. | — |
Secondary
| Measure | Time frame |
|---|---|
| Work-package 2: 1. The acceptability of eFI (electronic frailty index) will be measured using interview data collected at a single time point that will be analysed with Framework Analysis 2. The suitability of the endpoints for a future definitive study - this will be decided once the data from WP1 shows the link between eFI and risk of dying from chemotherapy and risk of admission during chemotherapy. If eFI has a predictive power (the poorer the eFI score the higher the chance of complications) this will be deemed as a suitable endpoint for a future trial 3. The overall accuracy between hospital derived eFI and GP-medical records derived eFIGP-eFI) - the eFI and GP-eFI will be directly compared to assess the difference in score 4. The ease of access to GP-eFI and HES eFI - this will be a descriptive analysis of the time it takes to extract data and obtain relevant agreements | — |
Countries
England, United Kingdom
Outcome results
None listed